<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is associated with a progressive decline in insulin-producing pancreatic β-cells, an increase in hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> production, and a decrease in insulin sensitivity </plain></SENT>
<SENT sid="1" pm="."><plain>The incretin hormones <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent insulinotropic <z:chebi fb="1" ids="15841">polypeptide</z:chebi> (GIP) and glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) stimulate <z:chebi fb="105" ids="17234">glucose</z:chebi>-induced insulin secretion; however, in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, the incretin system is impaired by loss of the insulinotropic effects of GIP as well as a possible reduction in secretion of GLP-1 </plain></SENT>
<SENT sid="2" pm="."><plain>Agents that modify GLP-1 secretion may have a role in the management of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The currently available incretin-based therapies, GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> (incretin mimetics) and dipeptidyl peptidase-4 (DPP-4) inhibitors (CD26 antigen inhibitors) [incretin enhancers], are safe and effective in the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>However, they may be unable to halt the progression of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, perhaps because they do not increase secretion of endogenous GLP-1 </plain></SENT>
<SENT sid="5" pm="."><plain>Therapies that directly target intestinal L cells to stimulate secretion of endogenous GLP-1 could possibly prove more effective than treatment with GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> and DPP-4 inhibitors </plain></SENT>
<SENT sid="6" pm="."><plain>Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> include G-protein-coupled receptor (GPCR) <z:chebi fb="4" ids="48705">agonists</z:chebi>, α-glucosidase inhibitors, peroxisome proliferator-activated receptor (PPAR) <z:chebi fb="4" ids="48705">agonists</z:chebi>, <z:chebi fb="0" ids="6801">metformin</z:chebi>, <z:chebi fb="0" ids="3098">bile acid</z:chebi> mimetics and <z:chebi fb="0" ids="3098">bile acid</z:chebi> sequestrants </plain></SENT>
<SENT sid="7" pm="."><plain>Both the GPCR <z:chebi fb="4" ids="48705">agonist</z:chebi> AR231453 and the novel <z:chebi fb="0" ids="3098">bile acid</z:chebi> mimetic INT-777 have been shown to stimulate GLP-1 release, leading to <z:mp ids='MP_0003058'>increased insulin secretion</z:mp> and <z:mp ids='MP_0005292'>improved glucose tolerance</z:mp> in mice </plain></SENT>
<SENT sid="8" pm="."><plain>Similarly, a study in insulin-resistant rats demonstrated that the <z:chebi fb="0" ids="3098">bile acid</z:chebi> sequestrant colesevelam increased GLP-1 secretion and improved <z:chebi fb="105" ids="17234">glucose</z:chebi> levels and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, the <z:chebi fb="0" ids="3098">bile acid</z:chebi> sequestrant colestimide (colestilan) has been shown to increase GLP-1 secretion and decrease <z:chebi fb="105" ids="17234">glucose</z:chebi> levels in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>; these results suggest that the <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering effects of <z:chebi fb="0" ids="3098">bile acid</z:chebi> sequestrants may be partly due to their ability to increase endogenous GLP-1 levels </plain></SENT>
<SENT sid="10" pm="."><plain>Evidence suggests that GPCR <z:chebi fb="4" ids="48705">agonists</z:chebi>, α-glucosidase inhibitors, PPAR <z:chebi fb="4" ids="48705">agonists</z:chebi>, <z:chebi fb="0" ids="6801">metformin</z:chebi>, <z:chebi fb="0" ids="3098">bile acid</z:chebi> mimetics and <z:chebi fb="0" ids="3098">bile acid</z:chebi> sequestrants may represent a new approach to management of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> via modification of endogenous GLP-1 secretion </plain></SENT>
</text></document>